Grifols, S.A.

Equities

GRF

ES0171996087

Pharmaceuticals

Market Closed - Bolsas y Mercados Espanoles 11:38:00 2023-11-28 am EST Intraday chart for Grifols, S.A. 5-day change 1st Jan Change
12.89 EUR -1.75% +1.14% +19.64%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Grifols Launches New Solution to Facilitate Pre-Transfusion Compatibility Testing in Multiple Myeloma Patients CI
Grifols Concludes Cohort 1 in Early-stage Alpha1-Antitrypsin Deficiency Treatment Trial MT
Grifols Completes Cohort 1 in Clinical Study of Alpha-1 15%, Evaluating First-In-Human Subcutaneous Dosing Option for Patients with Alpha1-Antitrypsin Deficiency CI
Travel, Pharma Stocks Lead European Equities Traded in the US as American Depositary Receipts Higher Tuesday MT
GRIFOLS : Persistently-high interest rate impacts our near-term estimates; fundamentals remain intact Alphavalue
Invest Securities Trims Grifols PT, Maintains Buy Rating MT
GRIFOLS : Healthy Q3; deleveraging priorities remain on track Alphavalue
European Equities Traded in the US as American Depositary Receipts Sharply Higher Thursday MT
Transcript : Grifols, S.A., Q3 2023 Earnings Call, Nov 02, 2023 CI
Grifols Affirms FY23 Revenue Guidance; Stock Jumps MT
Grifols shares soar after 2023 profit outlook upgrade RE
European Equities Traded in the US as American Depositary Receipts Rebound Wednesday After Slow Start MT
AIS Healthcare?s Advanced Infusion Care Announces Joint Study with Grifols to Continue Improving Patient Care CI
European Equities Traded in the US as American Depositary Receipts End Rough Week Lower Friday MT
European Equities Traded in the US as American Depositary Receipts Trend Lower Thursday MT
Grifols Unit Awarded Contract Expansion With US Defense Department to Develop Therapies for Botulinum Toxin MT
European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading MT
European Equities Traded in the US as American Depositary Receipts Rise Sharply Tuesday MT
Grifols Unit Partners With National Cancer Institute to Advance Development of Cancer Drug Candidate MT
Grifols Appoints Miguel Louzan as Chief Digital Information Officer CI
Fitch Changes Grifols Outlook to Negative Amid Increased Leverage MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Flat Tuesday MT
European Equities Traded in the US as American Depositary Receipts Trend Lower Friday MT
Grifols to Collaborate With Google Cloud for New Product Developments MT
European Equities Traded in the US as American Depositary Receipts Move Lower in Tuesday Trading MT
Chart Grifols, S.A.
More charts
Grifols, S.A. specializes in the research, development, manufacturing and marketing of therapeutic products and medical devices for use in hospitals and medical analysis laboratories. Net sales break down by family of products and services as follows: - products derived from plasma (77.3%): products for use by the pharmaceutical and biotechnology industries; - diagnostic machines and reagents (14.9%): in vitro hemophilic diagnostic equipment, coagulation analyzers, infectious serology reagents, etc. for use primarily by blood banks and transfusion centers; - hospital products (2.4%): non-biological surgical products, radiology and nutritional products, etc. for use by hospital pharmacies; - other (5.4%): primarily intermediate biological products and subcontracted manufacturing services. Net sales are distributed geographically as follows: Spain (5.3%), European Union (11.7%), the United States and Canada (63.6%) and other (19.4%).
More about the company
Trading Rating :
Investor Rating :
ESG Refinitiv :
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
12.89EUR
Average target price
18.48EUR
Spread / Average Target
+43.44%
Consensus
1st Jan change Capi. (M$)
+19.64% 8 589 M $
-8.81% 81 646 M $
-11.45% 38 459 M $
-17.88% 33 151 M $
-25.48% 25 148 M $
+15.19% 22 868 M $
-15.16% 16 689 M $
-7.88% 14 304 M $
-34.39% 11 849 M $
+32.84% 9 398 M $
Biopharmaceuticals
-40% off Black Friday : Our subscriptions help you unlock the best investment opportunities.
Enjoy this offer